Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc. on July 29, 2022, reporting events that occurred on July 25, 2022. The Company is a Delaware corporation with its principal executive offices in Bothell, WA, and its common stock trades on The Nasdaq Capital Market under the symbol "COCP".
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The report focuses exclusively on executive and director compensation adjustments.
Material Changes
On July 25, 2022, the Compensation Committee approved the following changes effective June 1, 2022:
- Executive Salary Increases: The annual base salary for James Martin (CFO and Co-Interim CEO) and Sam Lee (President and Co-Interim CEO) was increased from $350,000 to $385,000 each.
- Executive Bonuses and Options: Both executives received a $150,000 cash bonus and a grant of 300,000 incentive stock options each. The options have an exercise price of $0.42 per share, a ten-year term, and vest 50% on the one-year anniversary with the remainder vesting quarterly thereafter.
- Director Compensation: Independent directors received cash stipends ranging from $30,000 to $68,000 and stock option grants ranging from 80,000 to 280,000 options. These options share the same exercise price ($0.42) and vesting schedule as the executive grants.
- Delegation of Authority: The Co-Interim CEOs were granted authority to issue up to 400,000 stock options at their discretion under the 2015 Equity Incentive Plan for employees and select consultants.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on business performance, or discussion of risks and contingencies. The vesting of all granted options is subject to continuous employment or service as of each applicable vesting date.
Key Facts for Investor Verification
- Verify the total number of shares authorized under the 2015 Equity Incentive Plan to assess the impact of the new 400,000 option delegation and recent grants.
- Confirm the current market price of COCP stock relative to the $0.42 exercise price of the newly granted options.
- Review the Company's cash position to ensure liquidity is sufficient to cover the immediate cash bonuses ($300,000 to executives) and director stipends (approximately $230,000 total).
- Monitor future filings for the utilization of the discretionary 400,000 option grant authority.